Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13.9Revenue (TTM) $M0.0Net Margin (%)-48,257.9Altman Z-Score-93.5
Enterprise Value $M10.7EPS (TTM) $-0.7Operating Margin %-48,257.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-48,257.9Higher ROA y-yN
Price/Book8.510-y EBITDA Growth Rate %-18.8Quick Ratio1.6Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-5.6Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-170.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-224.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M26.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

RPRX is held by these investors:



RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-12-09Buy20,000$1.6-67.5view
Masterson Nola EDirector 2016-11-21Sell3,305$1.95-73.33view
PODOLSKI JOSEPHPresident and CEO 2016-02-18Buy10,000$0.93-44.09view
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.18-55.93view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-94.47view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-94.48view
Masterson Nola EDirector 2014-09-15Buy200$14.34-96.37view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-96.26view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-96.25view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-96.53view

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results May 09 2017 
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Apr 17 2017 
Repros Names Larry Dillaha, M.D., its Permanent President and CEO Apr 10 2017 
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids Apr 10 2017 
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results Mar 31 2017 
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase... May 18 2017
Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock May 17 2017
Repros Therapeutics reports 1Q loss May 09 2017
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results May 09 2017
What's in the Cards for Repros (RPRX) this Earnings Season? May 05 2017
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For... Apr 17 2017
Repros' Proellex Continues to be Under Partial Clinical Hold Apr 11 2017
Woodlands drug company names new top exec Apr 11 2017
Repros Therapeutics stock halted after FDA says partial clinical hold will continue for fibroids... Apr 10 2017
Repros Names Larry Dillaha, M.D., its Permanent President and CEO Apr 10 2017
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids Apr 10 2017
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results Mar 31 2017
Repros (RPRX) Q4 Earnings: What's in Store for the Stock? Mar 07 2017
Repros to Meet with the FDA for Phase III Proellex Program Dec 13 2016
How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers Dec 13 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)